Abstract:In a pancreatic tumor microenvironment, activated pancreatic stellate cells (PSCs) produce extracellular matrix (ECM) to form a barrier to drug penetration. Moreover, the interaction between cancer cells and activated PSCs promotes the tumor growth. Vitamin D receptor (VDR), as a key regulator to promote the recovery of PSCs to the resting state, is an attractive therapeutic target for pancreatic cancer. Herein, we reported the design and synthesis of 57 nonsecosteroidal VDR modulators based on the skeleton of phenyl-pyrrolyl pentane. Among them, compounds C4, I5, and I8 exhibited excellent VDR affinity and effective inhibition of the activation of PSCs, as well as potent suppression of the interaction between cancer cells and PSCs in vitro. In vivo, compound I5 combined with gemcitabine achieved efficacious antitumor activity without causing hypercalcemia. In conclusion, the compounds designed in our study can remodel the tumor microenvironment and are expected to be candidates for the treatment of pancreatic cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01197?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01197</a>.(Table S1) Cell toxicity of all target compounds against LTC-14; (Figure S1) cell toxicity of representative compounds against DSL-6A/C1 cells; (Figure S2) relative BLI intensities of mice that received different treatments; (Figure S3) inhibition rate of tumor growth after tumor-bearing mice received different treatments; (Figure S4) relative fluorescence intensities of α-SMA after mice received different treatments; (Figure S5) survival percentages of mice that received different treatments; (Figure S6) in vivo hypercalcemic effects in the orthotopic transplantation pancreatic cancer model; NMR spectra information; HPLC traces; and 1H NMR and 13C NMR spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01197/suppl_file/jm0c01197_si_001.pdf">PDF</a>)Molecular Formula Strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01197/suppl_file/jm0c01197_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression

Inhibition of P21 Activated Kinase Enhances Tumour Immune Response and Sensitizes Pancreatic Cancer to Gemcitabine

Abstract 3905: Epigenetic Primming Reveals the Central Role of Epigenetic State in the Anti-Tumor Activity of Vitamin D in Pancreatic Ductal Adenocarcinoma

Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a Vitamin D susceptible state

N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.

EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer

Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment

Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase

The Vitamin D Receptor Gene As a Determinant of Survival in Pancreatic Cancer Patients: Genomic Analysis and Experimental Validation

Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer

Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Exploring Epigenetic Dynamics Unveils a Super-Enhancer-Mediated NDRG1-β-Catenin Axis in Modulating Gemcitabine Resistance in Pancreatic Cancer

Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts

OXCT1 Enhances Gemcitabine Resistance Through NF-B Pathway in Pancreatic Ductal Adenocarcinoma

Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells.

Vitamin D and Pancreatic Ductal Adenocarcinoma—A Review of a Complicated Relationship

MicroRNA-410-3p Attenuates Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma by Inhibiting HMGB1-mediated Autophagy

Abstract 5111: VentX-modulated tumor associated macrophages revert immune suppression in tumor microenvironment and promote efficacy of gemcitabine against pancreatic cancer

ERK Signaling Pathway May Induce Gemcitabine Chemoresistance in Pancreatic Cancer Cell Line SW1990 by Regulating the Expression of Mdr-1 and RRM1 Gene